Aug 15 (Reuters) - Australia's CSL Ltd (CSL) on Tuesday posted an 8% rise in its annual profit, as strong growth in plasma collections with COVID-19 receding helped the biotech company counter the impact from currency fluctuations and higher costs.
The company posted a net profit after tax of $2.44 billion for the year ended June 30 on a constant currency basis, compared with $2.24 billion in fiscal 2022.
News: CSL Australia's CSL full-year profit rises as plasma collections soar
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$255.56 |
Change
-1.820(0.71%) |
Mkt cap ! $123.4B | |||
| Open | High | Low | Value | Volume |
| $256.32 | $256.50 | $252.60 | $88.97M | 349.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 45 | $255.51 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $255.57 | 28 | 4 |
View Market Depth
| Last trade - 13.44pm 21/07/2025 (20 minute delay) ? |
| CSL (ASX) Chart |